ARCHIVES

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

NCAB Says President’s Budget Would “Seriously Damage” Cancer Program

February 12, 1999

NCI Director Andrew von Eschenbach To Resign June 10, Remain As FDA Acting Commissioner.

June 2, 2006

Emory, Children’s Strengthen Ties

May 25, 2001

In Brief: Baylor Recruits Scardino, Osborne, 13 Others; Likely To Gain Its Second NCI SPORE Grants

April 30, 1999

In Brief: King Named To Replace Saunders; Zubrod Retires, Will Go To Miami; Perry acting Treatment Chief

June 14, 1974

SWOG Closes Prostate Cancer Trial With Mitoxantrone

February 23, 2007